Drugs / Galantamine
Galantamine
also known as
Reminyl · galantamine hydrobromide · galantamine HBr · Galantamine-ER · R113675 · Razadyne · (-)-galanthamine · Acumor xl · +26 more
Small molecule targets ACHE via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | RAZADYNE | — | 2001-02-28 | fda.gov ↗ |
Trials 71 · started per year
today
US approved 2001
1
3
1
1
1
6
4
8
9
4
3
4
5
1
3
2
3
3
1
3
1
1
1
1
1995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03124355 | Sep 2017 → Jun 2027 expected | postural orthostatic tachycardia syndrome | Vanderbilt University Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03014323 | Jan 2017 → Nov 2018 | — | Vanderbilt University Medical Center | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT00750529 | Nov 2008 → Sep 2013 | Alzheimer disease | University Hospital, Clermont-Ferrand | Completed | No outcome recorded |
| Phase 1 | NCT00645554 | ? → Sep 2004 | — | Xian-Janssen Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 1/23 trials · 1 met primary | ||||||
| Phase 1/2 | NCT04769206 | Dec 2021 → May 2027 expected | — | Vanderbilt University Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02872857 | Sep 2016 → Jul 2019 | subarachnoid hemorrhage | The University of Texas Health Science Center, Houston | Completed | No outcome recorded |
| Phase 1/2 | NCT02365285 | Mar 2015 → Oct 2017 | obesity disorder | Vanderbilt University Medical Center | Completed | Met primary |
| Phase 28 trials · 1 met primary | ||||||
| Phase 2 | NCT03384784 | Oct 2017 → May 2022 | AIDS dementia complex | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT02234752 | Sep 2014 → Jul 2016 | schizoaffective disorder, schizophrenia | Sheppard Pratt Health System | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01669538 | Aug 2012 → Nov 2017 | nicotine dependence | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01548638 | Feb → Aug 2012 | nicotine dependence | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT01100775 | May 2010 → Aug 2014 | schizophrenia | University of Maryland, Baltimore | Completed | Mixed |
| Phase 2 | NCT00809835 | Dec 2007 → Jan 2015 | cocaine dependence | Yale University | Completed | Met primary |
| Phase 2 | NCT00509067 | Nov 2007 → Mar 2011 | schizophrenia | Georgetown University | Completed | No outcome recorded |
| Phase 2 | NCT00416169 | May 2003 → Jul 2004 | frontotemporal dementia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT07625332 | Jun 2026 → Jun 2027 expected | metabolic syndrome X, spinal cord injury | Northwell Health | Recruiting | No outcome recorded |
| Phase 2/3 | NCT07003386 | Sep 2025 → Sep 2028 expected | ischemic stroke | Shanghai Yueyang Integrated Medicine Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT02248636 | Jan 2015 → Oct 2019 | dementia | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 2/3 | NCT00463879 | Sep 2005 → Sep 2007 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 324 trials · 5 met primary | ||||||
| Phase 3 | NCT02374567 | Jan 2015 → Jun 2017 | anxiety disorder, dementia, depressive disorder, schizophrenia +1 | Hannover Medical School | Terminated | No outcome recorded |
| Phase 3 | NCT00679627 | Jun 2008 → Apr 2012 | Alzheimer disease | Janssen Research & Development, LLC | Terminated | No outcome recorded |
| Phase 3 | NCT00814801 | Feb 2007 → Sep 2008 | Alzheimer disease | Janssen Pharmaceutical K.K. | Completed | Met primary |
| Phase 3 | NCT00082602 | May 2004 → Apr 2005 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00252603 | Apr 2004 → Apr 2007 | autism | University of Medicine and Dentistry of New Jersey | Completed | No outcome recorded |
| Phase 3 | NCT00645190 | Mar 2004 → Feb 2005 | Alzheimer disease | Xian-Janssen Pharmaceutical Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT00216593 | Dec 2003 → Sep 2007 | Alzheimer disease | Janssen Pharmaceutica N.V., Belgium | Completed | Mixed |
| Phase 3 | NCT00240695 | May 2003 → May 2004 | cognitive disorder, mental disorder | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00077727 | Mar 2003 → Feb 2005 | schizophrenia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00230997 | Dec 2002 → Aug 2004 | Lewy body dementia | Neurological Research Center | Completed | No outcome recorded |
| Phase 3 | NCT00035191 | Oct 2001 → Sep 2003 | vascular dementia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00216502 | Aug 2001 → Nov 2005 | Alzheimer disease, mental disorder | Janssen-Cilag S.p.A. | Completed | No outcome recorded |
| Phase 3 | NCT00236574 | May 2001 → Nov 2003 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00236431 | May 2001 → Dec 2003 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00301574 | Apr 2001 → Feb 2004 | Alzheimer disease | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT00253214 | Mar 2001 → Jul 2002 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00304629 | Mar 2000 → Mar 2002 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00261573 | Dec 1998 → Dec 2000 | Alzheimer disease, vascular dementia | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Met primary |
| Phase 3 | NCT00253227 | Jul 1997 → Dec 1998 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Met primary |
| Phase 3 | NCT00253188 | Feb 1997 → Dec 1998 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Met primary |
| Phase 3 | NCT00338117 | Aug 1995 → May 1997 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00000172 | — | Alzheimer disease | Janssen, LP | Completed | No outcome recorded |
| Phase 3 | NCT00309725 | ? → Oct 1999 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase 3 | NCT00253201 | ? → Oct 1997 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | Met primary |
| Phase 421 trials · 1 met primary · 4 missed | ||||||
| Phase 4 | NCT03454646 | Jun 2024 → Apr 2027 expected | Alzheimer disease | University Hospital, Bordeaux | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02283242 | Mar 2014 → Mar 2015 | abdominal obesity-metabolic syndrome | University of Sao Paulo | Completed | Met primary |
| Phase 4 | NCT01478633 | Sep 2011 → Jun 2013 | Alzheimer disease | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 4 | NCT01181921 | May → Jun 2011 | Alzheimer disease | Janssen-Cilag, S.A. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00741598 | Sep 2008 → May 2014 | bipolar disorder | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 4 | NCT00814658 | Jun 2008 → Oct 2009 | dementia | Janssen-Cilag Farmaceutica Ltda. | Completed | Missed primary |
| Phase 4 | NCT00369603 | Oct 2006 → Oct 2007 | Alzheimer disease | Duke University | Terminated | No outcome recorded |
| Phase 4 | NCT01054976 | Oct 2006 → Feb 2009 | Alzheimer disease | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT00226824 | Sep 2005 → May 2007 | Tourette syndrome | Parkinson's Disease and Movement Disorders Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT00219869 | Jul → Aug 2005 | brain injury, cognitive disorder, traumatic encephalopathy | Rapoport, Alan, M.D. | Unknown | No outcome recorded |
| Phase 4 | NCT00232349 | Feb 2005 → Jun 2007 | schizophrenia | Seattle Institute for Biomedical and Clinical Research | Terminated | No outcome recorded |
| Phase 4 | NCT01921972 | Nov 2004 → Nov 2008 | Alzheimer disease | Charite University, Berlin, Germany | Completed | Missed primary |
| Phase 4 | NCT00216515 | Mar 2004 → Nov 2005 | Alzheimer disease | Janssen Korea, Ltd., Korea | Completed | No outcome recorded |
| Phase 4 | NCT00320736 | Jan 2004 → May 2006 | schizoaffective disorder, schizophrenia | North Suffolk Mental Health Association | Completed | No outcome recorded |
| Phase 4 | NCT00423969 | Nov 2003 → Sep 2005 | depressive disorder | Indiana University | Terminated | No outcome recorded |
| Phase 4 | NCT00195845 | Apr 2003 → Sep 2006 | bipolar disorder | Cambridge Health Alliance | Completed | No outcome recorded |
| Phase 4 | NCT00227994 | Apr 2003 → Jan 2005 | stroke disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT00181675 | Dec 2002 → Sep 2003 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00176423 | May 2002 → Dec 2006 | schizoaffective disorder, schizophrenia | University of Maryland, Baltimore | Completed | Missed primary |
| Phase 4 | NCT00164242 | Jan 2002 → Oct 2004 | tardive dyskinesia | Caroff, Stanley N., M.D. | Completed | Missed primary |
| Phase 4 | NCT00035204 | ? → May 2003 | Alzheimer disease | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT02420327 | Sep 2014 → Mar 2017 | — | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT01362686 | Apr 2011 → Oct 2015 | Alzheimer disease | Indiana University | Terminated | No outcome recorded Stop: Enrollment |
| — | NCT00637442 | Feb 2008 → Dec 2010 | Alzheimer disease | University Hospital, Bonn | Unknown | No outcome recorded |
| — | NCT01029132 | Apr 2007 → Oct 2009 | dementia | Samsung Medical Center | Completed | No outcome recorded |
| — | NCT00161044 | Sep 2004 → Sep 2005 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| — | NCT00211588 | Jun 2004 → May 2007 | Parkinson disease | Memorial Hospital of Rhode Island | Unknown | No outcome recorded |
| — | NCT00181636 | ? → Oct 2006 | bipolar disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Comparator or background therapy23 trials | ||||||
| Phase 0 | NCT07208344 Background | Jul → Dec 2025 overdue | Alzheimer disease | Anhui Provincial Hospital | Recruiting | No outcome recorded |
| Phase 0 | NCT03547622 Comparator | May 2018 → Feb 2019 | — | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01417429 Comparator | Mar 2010 → Mar 2011 | substance withdrawal syndrome | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT01039194 Comparator | Jan → Apr 2010 | Alzheimer disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT00969696 Comparator | Aug 2009 → Jun 2011 | — | Yale University | Completed | No outcome recorded |
| Phase 2 | NCT01852110 Background | Oct 2013 → Apr 2016 | Alzheimer disease | Merck Sharp & Dohme LLC | Terminated | Missed primary |
| Phase 2 | NCT01677754 Background | Oct 2012 → Jun 2015 | Alzheimer disease | Hoffmann-La Roche | Completed | Missed primary |
| Phase 2 | NCT01416948 Comparator | Aug 2011 → Mar 2013 | post-traumatic stress disorder, traumatic brain injury | INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01508494 Comparator | Jun 2011 → Jun 2016 | cognitive disorder, stroke disorder | French National Institute of Health and Medical Research | Completed | No outcome recorded |
| Phase 2 | NCT01012167 Comparator | Feb 2010 → Jul 2014 | schizophrenia | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2/3 | NCT02098824 Comparator | Feb 2014 → Dec 2016 | vascular dementia | Amsterdam UMC, location VUmc | Unknown | No outcome recorded |
| Phase 3 | NCT05564169 Background | Jun 2026 → Dec 2028 expected | Alzheimer disease | AB Science | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT01872598 Background | Jan 2012 → Dec 2020 | Alzheimer disease | AB Science | Completed | No outcome recorded |
| Phase 3 | NCT02035982 Comparator | Jul 2010 → May 2014 | Alzheimer disease | Sunnybrook Health Sciences Centre | Completed | No outcome recorded |
| Phase 3 | NCT00566735 Comparator | Jul 2004 → Jan 2008 | bipolar depression, major depressive disorder, schizoaffective disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT07284290 Comparator | Dec 2025 → Nov 2029 expected | Lewy body dementia, Parkinson disease | Virginia Commonwealth University | Recruiting | No outcome recorded |
| Phase 4 | NCT00523666 Comparator | Sep 2006 → Sep 2008 | Alzheimer disease | Ludwig-Maximilians - University of Munich | Unknown | No outcome recorded |
| Phase 4 | NCT00626613 Background | — | Alzheimer disease | Jinan Mental Hospital | Unknown | No outcome recorded |
| — | NCT05102045 Background | Sep 2016 → May 2017 | Alzheimer disease | Istanbul Medipol University Hospital | Completed | No outcome recorded |
| — | NCT01880099 Comparator | Dec 2013 → Dec 2015 | nicotine dependence | Yale University | Completed | No outcome recorded |
| — | NCT01531153 Comparator | Sep 2011 → Jun 2016 | substance dependence | Yale University | Completed | No outcome recorded |
| — | NCT00606801 Comparator | Jun 2007 → Feb 2009 | cocaine abuse | Yale University | Completed | No outcome recorded |
| — | NCT01129479 Comparator | Oct 2004 → Dec 2007 | aphasia, stroke disorder | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2020-02-17 | Upsher-Smith Laboratories | Regulatory Sawai Receives Approvals for 15 Generic Drugs with 31 Strengths upsher-smith.com ↗
Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) received approvals by the Ministry of Health, Labour and Welfare for 15 generic drugs with 31 strengths. |
| 2011-02-03 | Sun Pharmaceutical Industries, Inc. | Regulatory Sun Pharma announces USFDA approval for generic Razadyne® ER sunpharma.com ↗
Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE:SUNPHARMA, BSE: 524715) announced that USFDA has granted its subsidiary an approval for an Abbreviated New Drug Application (ANDA) to market a generic version of Razadyne® ER, galantamine hydrobromide extended-release capsules. |
| 2007-08-30 | Sun Pharmaceutical Industries, Inc. | Regulatory USFDA grants tentative approval for Sun Pharma's ANDA for Galantamine tablets sunpharma.com ↗
USFDA has granted tentative approval for the company’s Abbreviated New Dr ug Application (ANDA) for generic Razadyne tm, galantamine tablets. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-17 | Upsher-Smith Laboratories | Sawai Receives Approvals for 15 Generic Drugs with 31 Strengths upsher-smith.com ↗ |
| 2011-02-03 | Sun Pharmaceutical Industries, Inc. | Sun Pharma announces USFDA approval for generic Razadyne® ER sunpharma.com ↗ |
| 2007-08-30 | Sun Pharmaceutical Industries, Inc. | USFDA grants tentative approval for Sun Pharma's ANDA for Galantamine tablets sunpharma.com ↗ |
Evidence & citations 39 cited values
Every value below carries the sentence it was read from. 97 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galantamine | “The investigators will identify Veterans who have been taking a cholinesterase inhibitor (CI) (donepezil or galantamine) for at least one year.” NCT02248636 ↗90“stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine, as per standard practice.” NCT01872598 ↗ “with either galantamine hydrobromide (AChEI + nicotinic receptor modulation) or donepezil hydrochloride (AChEI only)” NCT00369603 ↗ “Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.” NCT05102045 ↗ “Cholinesterase inhibitors (donepezil, rivastigmine or galantamine) and/or memantine” NCT05564169 ↗ “Galantamine: 16-24 mg total daily dose, administered orally” NCT01852110 ↗ “Galantamine - 8 mg and 16 mg and 24 mg” NCT02035982 ↗ |
| Known as | (-)-galanthamine | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Acumor xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Consion xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Elmino xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | GAL | “The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life” NCT00814658 ↗ |
| Known as | Galantamina | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | galantamine HBr | “Galantamine HBr, a tertiary alkaloid, is a competitive and reversible inhibitor of acetylcholinesterase” NCT00181675 ↗1“Galantamine HBr extended-release 8mg capsules (8mg ER).” NCT07284290 ↗ |
| Known as | galantamine hydrobromide | “Study medications will be given as a single dose before the Day 2 session which will produce ascending plasma drug levels (t= ½ 5/7 h) during the two hour testing session, in a...” NCT00463879 ↗2“The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.” NCT00216593 ↗ “with either galantamine hydrobromide (AChEI + nicotinic receptor modulation) or donepezil hydrochloride (AChEI only)” NCT00369603 ↗ |
| Known as | galantamine hydrobromide-ER | “The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease.” NCT01548638 ↗ |
| Known as | galantamine hydrochloride | “The proposed study will entail a comprehensive evaluation of the effects of acute doses of the nAChR allosteric modulator galantamine hydrochloride (0, 4 and 8 mg) on...” NCT00463879 ↗ |
| Known as | Galantamine-CR | “The purpose of the study is to determine whether the investigational drug galantamine-CR (Reminyl- Controlled Release capsule) is useful in improving problems with memory in...” NCT00181636 ↗ |
| Known as | Galantamine-ER | “Galantamine-ER for cognitive dysfunction in bipolar disorder and correlation with hippocampal neuronal viability: a proof-of-concept study.” PMID 19889129 ↗ 20091“Drug: Galantamine ER” NCT01548638 ↗ |
| Known as | Galanthamine hydrobromide | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Galsya xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Galzemic xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Gatalin xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Gazylan xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Jilkon hydrobromide | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Lotprosin xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Luventa xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Lycoremine hydrobromide | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Nivalin | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Nivaline | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | NSC-100058 | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | R113675 | “Placebo-Controlled, Double-Blind Study of Galantamine (R113675) in the Treatment of Alzheimer's Disease.” NCT00301574 ↗1“Placebo-controlled Confirmatory Study of Galantamine (R113675) for Alzheimer's Type Dementia” NCT00814801 ↗ |
| Known as | Razadyne | “This is a preliminary open-label study to determine whether a medication called galantamine (Brand Name: Razadyne) will help smokers quit and whether it reduces cognitive...” NCT01548638 ↗ |
| Known as | Razadyne er | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Reminyl | “Galantamine (Trade name: Reminyl) is a new FDA-approved selective acetylcholinesterase inhibitor (AChEI), which may also allosterically modulate nicotinic receptors, enhance...” NCT00176423 ↗4“Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial.” PMID 19042161 ↗ Nov 2008 “Galantamine (Reminyl®)” NCT00523666 ↗ |
| Known as | Reminyl ER | “The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life” NCT00814658 ↗ |
| Known as | Reminyl PRC | “The primary objective is the assessment of the modulating effect of galantamine (Reminyl PRC) on circadian rhythm (wake/sleep) in patients with moderate Alzheimer's disease.” NCT01181921 ↗ |
| Known as | Reminyl xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Reminyl- Controlled Release capsule | “The purpose of the study is to determine whether the investigational drug galantamine-CR (Reminyl- Controlled Release capsule) is useful in improving problems with memory in...” NCT00181636 ↗ |
| Known as | Tamilin | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Known as | Zeebral xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL659 ↗ |
| Action | Inhibit | “It inhibits an enzyme that breaks down acetylcholine” NCT00000172 ↗1“Acetylcholinesterase inhibitor” CHEMBL659 ↗ |
| Modality | Small molecule | “Galantamine HBr, a tertiary alkaloid” NCT00181675 ↗ |
| Route | Oral | “Galantamine will be given by mouth 4mg twice daily for Weeks 1-4 and then 8mg twice daily for Weeks 5-8 and beyond” NCT00035204 ↗ |
| Target | ACHE | “Acetylcholinesterase inhibitor” CHEMBL659 ↗ |